PriceTargets.com logo

iRadimed - IRMD Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $120.00
  • Forecasted Upside: 56.49%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$76.68 As of 10/30/2026 05:00 PM ET
▼ -9.06 (-10.57%)

This chart shows the closing price for IRMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New iRadimed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IRMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IRMD

Analyst Price Target is $120.00
▲ +56.49% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for iRadimed in the last 3 months. The average price target is $120.00, with a high forecast of $120.00 and a low forecast of $120.00. The average price target represents a 56.49% upside from the last price of $76.68.

This chart shows the closing price for IRMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 6 investment analysts is to moderate buy stock in iRadimed. This rating has held steady since July 2026, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2026
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2026
  • 1 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2026
  • 1 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2026
  • 1 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2026

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/16/2026Weiss RatingsUpgradeHold (C+) ➝ Buy (B-)
10/2/2026Weiss RatingsDowngradeBuy (B-) ➝ Hold (C+)
9/22/2026Needham & Company LLCInitiated CoverageHold
9/9/2026Weiss RatingsUpgradeHold (C+) ➝ Buy (B-)
8/3/2026Weiss RatingsDowngradeBuy (B-) ➝ Hold (C+)
5/20/2026Weiss RatingsDowngradeBuy (B) ➝ Buy (B-)
5/6/2026Weiss RatingsUpgradeBuy (B-) ➝ Buy (B)
4/2/2026Freedom CapitalUpgradeStrong-Buy
2/11/2026Lake Street CapitalReiterated RatingBuy ➝ Buy$120.00
2/10/2026Roth CapitalReiterated RatingBuy ➝ Buy$120.00
12/29/2025Weiss RatingsReiterated RatingBuy (B-) ➝ Buy (B-)
12/22/2025Weiss RatingsReiterated RatingBuy (B-) ➝ Buy (B-)
12/16/2025Weiss RatingsReiterated RatingBuy (B-) ➝ Buy (B-)
12/10/2025Weiss RatingsReiterated RatingBuy (B-) ➝ Buy (B-)
12/4/2025Weiss RatingsReiterated RatingBuy (B-) ➝ Buy (B-)
11/4/2025Zacks ResearchUpgradeHold
11/3/2025Lake Street CapitalReiterated RatingBuy ➝ Buy$100.00
10/31/2025Roth CapitalSet Target$90.00
10/31/2025Roth CapitalReiterated RatingBuy ➝ Buy
10/31/2025Weiss RatingsReiterated RatingBuy (B) ➝ Buy (B)
10/8/2025Weiss RatingsReiterated RatingBuy (B-) ➝ Buy (B-)
9/27/2025Weiss RatingsReiterated RatingBuy (B-) ➝ Buy (B-)
2/14/2025Roth CapitalReiterated RatingBuy ➝ Buy$60.00 ➝ $72.00
8/2/2024Roth CapitalLower TargetBuy ➝ Buy$65.00 ➝ $60.00
4/22/2024Roth CapitalReiterated RatingBuy$65.00
4/1/2024Singular ResearchReiterated RatingBuy
8/3/2023Lake Street CapitalBoost Target$55.00 ➝ $60.00
4/12/2023Lake Street CapitalInitiated CoverageBuy$50.00
2/6/2023MKM PartnersBoost Target$46.00 ➝ $48.00
11/2/2021Roth CapitalBoost TargetBuy$36.00 ➝ $42.00
(Data available from 10/30/2021 forward)

News Sentiment Rating

0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2026
  • 4 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2026
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2026
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2026
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2026
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2026

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

iRadimed logo
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Read More

Today's Range

Now: $76.68
Low: $76.35
High: $82.28

50 Day Range

MA: $85.66
Low: $76.68
High: $89.83

52 Week Range

Now: $76.68
Low: $76.35
High: $107.90

Volume

218,003 shs

Average Volume

105,373 shs

Market Capitalization

$980.74 million

P/E Ratio

47.90

Dividend Yield

0.93%

Beta

0.91

Frequently Asked Questions

What sell-side analysts currently cover shares of iRadimed?

The following equities research analysts have issued reports on iRadimed in the last twelve months: Freedom Capital, Lake Street Capital, Needham & Company LLC, Roth Capital, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for IRMD.

What is the current price target for iRadimed?

0 Wall Street analysts have set twelve-month price targets for iRadimed in the last year. Their average twelve-month price target is $120.00, suggesting a possible upside of 56.5%. Lake Street Capital has the highest price target set, predicting IRMD will reach $120.00 in the next twelve months. Lake Street Capital has the lowest price target set, forecasting a price of $120.00 for iRadimed in the next year.
View the latest price targets for IRMD.

What is the current consensus analyst rating for iRadimed?

iRadimed currently has 2 hold ratings, 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for IRMD.

What other companies compete with iRadimed?

Other companies that are similar to iRadimed include Integer, iRhythm Technologies, Pulse Biosciences, AtriCure and TransMedics Group. Learn More about companies similar to iRadimed.

How do I contact iRadimed's investor relations team?

iRadimed's physical mailing address is 12705 Ingenuity Drive, Orlando, FL, 32826. The medical equipment provider's listed phone number is (407) 677-8022 and its investor relations email address is [email protected]. The official website for iRadimed is www.iradimed.com. Learn More about contacing iRadimed investor relations.